Keros Therapeutics (NASDAQ:KROS) Director Sells $28,140.00 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Alpna Seth sold 2,625 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the transaction, the director directly owned 9,767 shares in the company, valued at approximately $104,702.24. This represents a 21.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock opened at $10.30 on Monday. Keros Therapeutics, Inc. has a one year low of $9.79 and a one year high of $22.55. The stock’s fifty day moving average is $11.33 and its 200 day moving average is $15.15. The stock has a market cap of $203.84 million, a P/E ratio of -3.42 and a beta of 0.94.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). The company had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.93 million. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%. Analysts predict that Keros Therapeutics, Inc. will post -5.19 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Western Standard LLC grew its holdings in shares of Keros Therapeutics by 42.7% in the third quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock valued at $34,644,000 after purchasing an additional 654,989 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Keros Therapeutics by 282.5% in the fourth quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock valued at $12,047,000 after purchasing an additional 436,986 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Keros Therapeutics in the second quarter valued at $4,251,000. Caption Management LLC grew its holdings in shares of Keros Therapeutics by 114.1% in the second quarter. Caption Management LLC now owns 36,078 shares of the company’s stock valued at $482,000 after purchasing an additional 291,997 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its holdings in shares of Keros Therapeutics by 683.7% in the third quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock valued at $4,795,000 after purchasing an additional 264,445 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Analyst Upgrades and Downgrades

KROS has been the topic of a number of recent analyst reports. Wells Fargo & Company decreased their price target on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Weiss Ratings cut Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Finally, Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Keros Therapeutics has a consensus rating of “Hold” and a consensus price target of $20.40.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.